Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 10/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.32 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309392 | 0.92 | BRD4 (0.37) | BRD4EGFRIGF1RTNK2HRH4 | |
| SCHEMBL24309916 | 0.88 | EGFR (0.39) | EGFRIGF1RHRH4CTSCMAP4K1 | |
| SCHEMBL24310153 | 0.87 | CTSC (0.36) | BRD4EGFRIGF1RTNK2HRH4 | |
| SCHEMBL24309843 | 0.86 | CTSC (0.41) | EGFRIGF1RTNK2HRH4CTSC | |
| SCHEMBL24310715 | 0.86 | CSF1R (0.35) | EGFRIGF1RTNK2HRH4CTSC | |
| SCHEMBL24309796 | 0.85 | ALK (0.33) | BRD4EGFRIGF1RTNK2 | |
| SCHEMBL29566568 | 0.84 | HTR2C (0.39) | BRD4EGFRIGF1RTNK2NUAK1 | |
| SCHEMBL24310685 | 0.84 | HTR2C (0.39) | BRD4EGFRIGF1RTNK2NUAK1 | |
| SCHEMBL24309897 | 0.84 | DHODH (0.32) | IGF1RMAP4K1 | |
| SCHEMBL24309882 | 0.82 | MAP4K1 (0.37) | BRD4EGFRIGF1RTNK2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |